- Datum25.09.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalterstock3
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenVertex Pharmaceuticals Inc. Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
Nasdaq | VK | |||||
L&S | VK | |||||
Tradegate | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Vertex Pharmaceuticals Inc.
Webinar zu Vertex Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)341,850-510,635
- Jahrestief / Hoch ($)391,010-510,635
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Vertex Pharmaceuticals Inc.
Termine von Vertex Pharmaceuticals Inc.
- Okt30Vertex Pharmaceuticals Inc.Q3 2024 Earnings Release
- Feb11Vertex Pharmaceuticals Inc.Q4 2024 Earnings Release
- Apr30Vertex Pharmaceuticals Inc.Q1 2025 Earnings Release
Beschreibung
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.